Title: Comparison of Minimum Inhibition Concentration (MIC) as Measured by Etests and Agar

Dilution in *Neisseria gonorrhoeae* Isolates Tested from 2018-2024

Joshua A. Manuel BS[1†], Jennifer J. Wenner MA[1,4, †], Michael E. DeWitt MS[1,2,4], Brinkley R.

Bellotti PhD[1], Cindy Toler BSMT (ASCP), MBA [4], Elizabeth Palavecino MD [1,3], Candice J.

McNeil MD MPH[1,4*]

1. Section on Infectious Diseases, Department of Medicine, Wake Forest University School of

Medicine, Winston-Salem, NC, USA

2. Department of Biology, Wake Forest University, Winston-Salem, NC, USA

3. Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC,

USA

4. North Carolina Strengthening the United States Response to Resistant Gonorrhoea (SURRG)

Guilford County Department of Public Health, Greensboro, NC, USA

† These authors contributed equally.

*Corresponding Author:

Dr. Candice J. McNeil MD

Section on Infectious Disease

Wake Forest University School of Medicine

Medical Center Boulevard

Winston-Salem, NC 27157

(336)-716-4070; cmcneil@wakehealth.edu

Text: 2141 words   Figures: 1   Tables: 10   References: 30

Conflicts of Interest- CJM has received grants, contracts and/or participated in clinical trials with Biomedical Advanced Research and Development Authority/GlaxoSmithKline, Becton Dickinson, United States Centers for Disease Control and Prevention, Cepheid, Gilead, Hologic, National Institutes of Health paid to her employer. MD, BB, and JW acknowledge support from United States Centers for Disease Control and Prevention paid to their employer.

Sources of Support- Funding for the Strengthening the U.S. Response to Resistant Gonorrhea activities described in this article were supported with federal Antibiotic Resistance Initiative funding and administered through the U.S. Centers for Disease Control and Prevention's (CDC) Epidemiology and Laboratory Capacity for the Prevention and Control of Infectious Diseases (ELC) Cooperative Agreement Grant Award Number CK19-1904.

Funders had no role in study design; collection, analysis, and interpretation of data; in writing the report; and in the decision to submit this correspondence for publication.

IRB exemption was granted for this study by the Wake Forest Health Sciences Institutional Review Board (IRB number IRB00102035).

Short Summary

A comparison of two antimicrobial susceptibility testing methods, agar dilution and Etest, for

determining the MICs of several antimicrobial agents against Neisseria *gonorrhoeae* revealed

high levels of concordance between the two testing methods.

Abstract

Background

In the U.S. *Neisseria gonorrhoeae* is the second most common reportable STI amassing 601,319

cases in 2023. Notably, *N. gonorrhoeae* has developed antimicrobial resistance, necessitating

ongoing surveillance. In response to this threat, the U.S. Centers for Disease Control and

Prevention (CDC) has established antimicrobial resistance surveillance networks including

Strengthening the U.S. Response to Resistant Gonorrhea (SURRG) and the Antibiotic Resistance

Lab Network (ARLN). SURRG performs testing using a gradient strip method, the Etest, while

ARLN labs perform testing by agar dilution, for determining MIC values for *N. gonorrhoeae*.

Methods

We compared the concordance of MIC values obtained using the Etest gradient strip method at a

SURRG site in North Carolina compared to ARLN using the agar dilution method for three

antibiotics: azithromycin, cefixime, and ceftriaxone.

The MIC values and the corresponding interpretations for each agent were analyzed according to

the recommendations of the Clinical and Laboratory Standards Institute (CLSI). The essential

agreements were assessed

Results

Between January 2018 and December 2024, a total of 1,951 *N. gonorrhoeae* had corresponding

isolates from the ARLN lab available for comparison of which 1,892 had corresponding Etest

and agar dilution results for all three antibiotics. We found high levels of agreement between

both testing methods for each antimicrobial agent tested over six years including for strains

isolated from distinct anatomical sampling sites.

Conclusions

The Etest method provides a robust alternative for accurately detecting antibiotic-resistant *N.*

gonorrhoeae for public health surveillance, which may make them particularly useful in

resource- or labor-limited settings.

Key Words: *Neisseria gonorrhoeae*, Etest, Minimum Inhibitory Concentration, Antibiotic

Resistance, Agar Dilution

Introduction

Neisseria gonorrhoeae is the second most common reportable STI amassing 648,056 cases in 2023 [1]. *N. gonorrhoeae* antimicrobial resistance has steadily increased rendering multiple classes of antibiotics ineffective, leaving ceftriaxone, a third-generation cephalosporin, as the front-line treatment for *N. gonorrhoeae* [2-7]. This emergence of drug resistance has produced the critical need for robust surveillance and testing methodologies to monitor and combat the spread of antibiotic-resistant strains.

In response to growing concern surrounding antimicrobial resistance, the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have established extensive antimicrobial resistance surveillance networks [8,9]. These networks play pivotal roles in monitoring the prevalence and spread of antibiotic resistance, identifying emerging resistance patterns, and informing public health interventions aimed at mitigating the spread of resistant strains. Despite these efforts, low- and middle-income countries are at higher risk for antimicrobial resistant pathogen spread in large part due to limited resource and labor allocation towards high quality surveillance [10,11].

The gold standard method for antimicrobial susceptibility testing and determination of minimum inhibitory concentration (MIC) in *N. gonorrhoeae* is via the agar dilution method. Though accurate, this method used mostly by reference laboratories is relatively complex and time consuming. It involves plating a standardized inoculum of bacteria on multiple agar plates, each containing antibiotics at doubling dilution concentrations. In contrast, the Etest gradient method (bioMerieux, Durham, NC) uses a plastic strip impregnated with a gradient of antimicrobial

agents on a lawn of bacteria, offering a simpler and more practical alternative for determining

MIC values. For this reason, the Etest and other gradient diffusion methods have become

increasingly popular in clinical laboratories due to their ease of use and reduced labor

requirements [12]. They may be especially beneficial in settings with a low volume of specimens

for antimicrobial susceptibility testing. Many previous studies provide evidence that Etests are a

reliable method for determining *N. gonorrhoeae* MIC values for several drugs [13-15], yet

discordance between agar dilution and Etests has been reported, potentially due to differences in

technique or reading expertise [16-18]. Establishing that there exists agreement between both

tests is paramount given the use of both methods for surveillance.

In this study, we assess the concordance between the agar dilution and Etest methods in

determining the *N. gonorrhoeae* MIC values of three antimicrobials azithromycin, cefixime, and

ceftriaxone. Though azithromycin is no longer a component of *N. gonorrhoeae* treatment in the

U.S, we have included it here to highlight historic trends. Using data from laboratories

participating in two CDC-supported antibiotic resistance surveillance networks; the Antibiotic

Resistance Lab Network (ARLN) and the Guilford County, North Carolina Public Health

Department as part of the Strengthening the U.S. Response to Resistant Gonorrhea (SURRG)

project [10], which employ agar dilution and Etests methods respectively, we characterize the

concordance (essential agreement) in MIC values over time and by specimen source. We also

analyze the ability of the Etest to measure MIC within the same susceptibility category of agar

dilutions (categorical agreement). High levels of agreement between both testing methods

confirms that the Etest method can be used or accurately detecting antibiotic-resistant *N.*

gonorrhoeae for public health surveillance purposes, which may make them particularly useful

in resource- or labor-limited settings.

Materials and Methods

Specimens collected from the endocervix, pharynx, rectum, urethra and vagina as part of

SURRG activities were submitted to the North Carolina SURRG laboratory for culture and

susceptibility testing by Etest for azithromycin, cefixime, and ceftriaxone. *N. gonorrhoeae*

organisms isolated from positive specimens were initially tested by Etest at the NC SURRG

laboratory and then submitted for MIC confirmation by the agar dilution method at the CDC-

assigned regional Antimicrobial Resistance Laboratory Network (ARLN) in Tennessee, which in

addition to azithromycin, cefixime, and ceftriaxone, performs a broader susceptibility panel.

Antimicrobial susceptibility testing (AST) data from January 2018 to December 2024 were

compared for the two methods performed on the same organism to assess concordance of MIC

results.

The testing methods slightly differ in the individual MIC concentration levels that are tested and

reported, and some of the lower dilutions tested were slightly different throughout the years

Changes in Etest resolution, or in other words differences in minimum reportable MIC

concentration values over time also led to discrepancy between recordable values. To better

illustrate these differences, see Supplemental Tables 1-4 in Supplemental Digital Content 1 for

all MIC pairs and the concentrations each lab reports for the three antibiotics with specifications

on which MIC values are assumed to be at equivalent concentration levels.

Essential agreement of an MIC result was defined as an MIC within +/- 1 dilution between the

Etest compared to the reference MIC result obtained by agar dilution method. The CLSI M52

guideline for acceptable performance among clinical trial data for manufacturers states >=90% of

testing results should be in essential agreement [19]. MIC value pairs on the same row of

Supplemental Tables 1-4 or on two adjacent rows would be in essential agreement. Results are

provided for exact MIC equivalency among pairs as well as results for pairs that are within ± 1

level (essential agreement). In Tables 2-9, negative dilution differences suggest a lower value

recorded by the Etest as compared to agar dilution, whereas positive dilution differences suggest

a higher MIC value recorded.

Essential agreement for MIC results is reported as a percentage calculated by the number of all

pairs that are considered in essential agreement (± 1 level) divided by the total number of tested

pairs. Results are reported across the entire collection time and a yearly time series for each

antibiotic; also, a subgroup analysis was performed to assess the results by site of the specimen

source. Spearman's rank correlation coefficient was used to further measure the association

between the reported MIC's ranked level. For MIC pairs not reported as in essential agreement, a

two-sided two-sample proportion test with continuity correction was performed to assess if the

SURRG lab tends to report lower or higher than the ARLN lab.

Designations for susceptibility categories and alerts for risk of resistance emergence for each

sample were made using the 2020 CDC Treatment Guidelines for gonorrhea [20]. Cutoffs for

alerts were MIC ≥0.125 μg/mL for ceftriaxone, ≥0.25 μg/mL for cefixime, and ≥2 μg/mL for

azithromycin. Major disagreements between Etests and the agar dilutions were determined as

pairs in which one MIC triggered an alert for potential emerging resistance by one method and

the other method did not.

Results

A total of 1,951 SURRG samples had corresponding samples from the ARLN lab available for

comparison between January 2018 and December 2024, of which 1,852 had results for all three

antibiotics. The remaining contained missing values for at least one lab result. The sample sizes

for each can be seen in Table 1, along with the Spearman's rank correlation coefficient of the

ranked pairs, which is significant for all three antibiotics indicating a positive association

between the SURRG and ARLN lab results.

Essential Agreement

Overall, MIC essential agreement for azithromycin, cefixime, and ceftriaxone was 95%, 98%,

and 95% respectively (Table 2). The SURRG lab has maintained >86% essential agreement each

year for all three antibiotics compared. These yearly essential agreement rates can also be seen in

Figure 1 alongside the yearly equivalence rates and in Tables 3-5; yearly essential agreement

ranged from 91% to 98% for azithromycin, 96% to 99.7% for cefixime, and 86% to 99.5% for

ceftriaxone.

For all three antibiotics, the Etest gave a lower MIC value more often than a higher MIC value

MIC compared to the agar dilution method. 77%, 74% and 80% of all non-essential agreements

were due to lower MIC readings by Etest for azithromycin, cefixime and ceftriaxone respectively

(Table 6).

Subgroup Analysis by Specimen Site

Specimens were collected from 6 different anatomical sites (Tables 7-9). For all antibiotics and

organisms isolated from different specimen sites, the essential agreement was ≥ 93%.

Susceptibility Category/Emerging Resistance Alert Analysis

The number of major disagreements in alert values, or in other words, the times in which the

agar dilution method and Etests did not both alert for potential emerging resistance, were 49, 4

and 1 time for azithromycin, cefixime and ceftriaxone respectively (Table 10).

Discussion

Overall, we found that all three antimicrobials, with the exception of ceftriaxone in 2023 and

2024, achieved above the CLSI standard 90% level of essential agreement between agar dilutions

and Etests across all years and inoculation sites for *Neisseria gonorrhoeae* MIC. Furthermore,

major categorical disagreement for the preferred frontline antibiotic, ceftriaxone, occurred only

once in nearly 2000 specimens tested. For MIC values that were not identical between the two

methods, the Etest more often provided lower MICs. Importantly, these findings were consistent

over a seven-year period, highlighting the potential utility of Etests for MIC determination in

resource-limited settings. This approach may be especially valuable for detecting resistant *N*.

gonorrhoeae strains and monitoring resistance trends in areas that might otherwise lack the

capacity for agar dilution

Etest agreement remained consistent over time, even in the face of potential challenges such as

staff turnover and variability in testing procedures or supplies. Notably, the downward trend in

agreement for ceftriaxone, which was likely caused by the SURRG lab's change to Etest strips

with lower maximum and minimum antibiotic concentrations in late 2019, highlights the

vulnerability of longitudinal MIC comparison to changes in methods. However, this

disagreement also provides evidence for the robustness of Etests to provide accurate results, with

the lowest level of agreement across all years still just below the FDA threshold at 86% essential

agreement. The Etests robustness is further supported by its ability to avoid major categorical

disagreements, or times when the Etest produces an MIC which disagrees with the agar dilutions

MIC in such a way that the sample is incorrectly interpreted as susceptible or resistant,

potentially changing drug choice for targeted therapy. For ceftriaxone, there was only one major

disagreement out of the nearly 2,000 samples analyzed as well as similarly low rates of

disagreement for azithromycin and cefixime. In other words, despite ceftriaxone falling below

90% agreement two years, the susceptibility category the Etest placed the sample in was

identical to agar dilution in all but one specimen.

The Etest's tendency to provide a lower MIC value compared to agar dilution is consistent with

Liu et al. who previously described this finding in a similar study with only 105 *N. gonorrhoeae*

isolates [16]. Unlike this study, however, our results cannot be explained by reading to the finer

increments available on Etests. Though there is a subjective component to this test, results that

seemed outside the range or unusual were always confirmed by a secondary reader. The SURRG

lab reads and reports the MIC to the nearest doubling dilutions which match the antibiotic

concentrations used in the standard agar dilutions per CDC reporting guidelines. Etests providing

lower MIC values is seen across many drug classes and bacterial species [21-25] making it

difficult to pinpoint an explanation for these results, but it seems more related to the Etest

method rather than the organism tested.

Essential agreement across different anatomical sites is a crucial finding for confidence in Etests

as an alternative for antibiotic resistance surveillance of *N. gonorrhoeae* isolated from different

specimen types. Prioritizing speed and quickly accessible results in the context of public health

surveillance has the potential to make MIC measurement more prone to causes for error. For

example, specimen types harboring more extensive microbiomes, such as from the pharynx and

rectum which are known to harbor other commensal *Neisseria* species [26], may coincide with

contamination leading to difficulty in sample isolation for MIC measurement. Furthermore,

heteroresistance, a phenomenon in which populations of bacteria contain minority-resistant

subpopulations [27] has previously been described in *N. gonorrhoeae* [28], would cause

discordance between Etests and agar dilutions due to the indeterminately large number of cells

being tested on an Etest lawn, $>10^7$ CFU and 10^4 CFU respectively [29]. Different infection sites

offer alternative selection pressures which may fuel greater genetic diversity amongst sampled

populations. The environmental differences between anatomical sites include but are not limited

to differences in opportunity for refuge from the immune system, variability in antibiotic

concentration, nutrient availability and competition with other microbial populations, all of

which provide unique growth opportunities and selection pressures that may result in the

evolution of heteroresistance [30]. The high rates of concordance between the two tests further

emphasize the strength of Etests to make accurate MIC determinations in spite of these potential

causes for error.

Our results provide evidence that the Etest method offers a less labor-intensive alternative to agar

dilution for antimicrobial susceptibility testing for *N. gonorrhoeae* and is suitable for use in a

public health setting processing small volumes of specimens, which can potentially be leveraged

in low-resource or low volume labs which require rapid results in individual specimens. The

Etest method offers a robust alternative to the more laborious agar dilution method for

surveillance of antibiotic-resistant *N. gonorrhoeae*.

References

1.   Centers for Disease Control and Prevention. Sexually Transmitted Infections Surveillance

2023. Atlanta: US Department of Health and Human Services; 2024.

https://www.cdc.gov/std/statistics/2022/default.htm

2.   Lin EY, Adamson PC, Klausner JD. Epidemiology, Treatments, and Vaccine

Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future

Directions. Drugs. 2021;81(10):1153-69. Epub 20210607. doi: 10.1007/s40265-021-01530-0.

PubMed PMID: 34097283; PubMed Central PMCID: PMCPMC8182353.

3.   Quillin SJ, Seifert HS. Neisseria gonorrhoeae host adaptation and pathogenesis. Nat Rev

Microbiol. 2018;16(4):226-40. Epub 20180212. doi: 10.1038/nrmicro.2017.169. PubMed PMID:

29430011; PubMed Central PMCID: PMCPMC6329377.

4.   Costa-Lourenco A, Barros Dos Santos KT, Moreira BM, Fracalanzza SEL, Bonelli RR.

Antimicrobial resistance in Neisseria gonorrhoeae: history, molecular mechanisms and

epidemiological aspects of an emerging global threat. Braz J Microbiol. 2017;48(4):617-28.

Epub 20170712. doi: 10.1016/j.bjm.2017.06.001. PubMed PMID: 28754299; PubMed Central

PMCID: PMCPMC5628311.

5.   van Duin D, Paterson DL. Multidrug-Resistant Bacteria in the Community: An Update.

Infect Dis Clin North Am. 2020;34(4):709-22. Epub 20200930. doi: 10.1016/j.idc.2020.08.002.

PubMed PMID: 33011046; PubMed Central PMCID: PMCPMC8713071.

6.   Yahara K, Ma KC, Mortimer TD, Shimuta K, Nakayama SI, Hirabayashi A, et al.

Emergence and evolution of antimicrobial resistance genes and mutations in Neisseria

gonorrhoeae. Genome Med. 2021;13(1):51. Epub 20210330. doi: 10.1186/s13073-021-00860-8.

PubMed PMID: 33785063; PubMed Central PMCID: PMCPMC8008663.

7.   Ayala JC, Balthazar JT, Shafer WM. Transcriptional regulation of the mtrCDE efflux

pump operon: importance for Neisseria gonorrhoeae antimicrobial resistance. Microbiology

(Reading). 2022;168(8). doi: 10.1099/mic.0.001231. PubMed PMID: 35916832; PubMed

Central PMCID: PMCPMC10235802.

8.   Weston EJ, Wi T, Papp J. Strengthening Global Surveillance for Antimicrobial Drug-

Resistant Neisseria gonorrhoeae through the Enhanced Gonococcal Antimicrobial Surveillance

Program. Emerg Infect Dis. 2017;23(13):S47-52. doi: 10.3201/eid2313.170443. PubMed PMID:

29155673; PubMed Central PMCID: PMCPMC5711314.

9.   Kersh EN, Pham CD, Papp JR, Myers R, Steece R, Kubin G, et al. Expanding U.S.

Laboratory Capacity for Neisseria gonorrhoeae Antimicrobial Susceptibility Testing and Whole-

Genome Sequencing through the CDC's Antibiotic Resistance Laboratory Network. J Clin

Microbiol. 2020;58(4). Epub 20200325. doi: 10.1128/JCM.01461-19. PubMed PMID:

32024723; PubMed Central PMCID: PMCPMC7098741.

10.   Schlanger K, Learner ER, Pham CD, Mauk K, Golden M, Wendel KA, et al.

Strengthening the US Response to Resistant Gonorrhea: An Overview of a Multisite Program to

Enhance Local Response Capacity for Antibiotic-Resistant Neisseria gonorrhoeae. Sex Transm

Dis. 2021;48(12S Suppl 2):S97-S103. doi: 10.1097/OLQ.0000000000001545. PubMed PMID:

34475362; PubMed Central PMCID: PMCPMC10275356.

11.   Vernet G, Mary C, Altmann DM, Doumbo O, Morpeth S, Bhutta ZA, Klugman KP.

Surveillance for antimicrobial drug resistance in under-resourced countries. Emerg Infect Dis.

2014;20(3):434-41. doi: 10.3201/EID2003.121157. PubMed PMID: 24564906; PubMed Central

PMCID: PMCPMC3944851.

12.   Iskandar K, Molinier L, Hallit S, Sartelli M, Hardcastle TC, Haque M, et al. Surveillance

of antimicrobial resistance in low- and middle-income countries: a scattered picture. Antimicrob

Resist Infect Control. 2021;10(1):63. Epub 20210331. doi: 10.1186/s13756-021-00931-w.

PubMed PMID: 33789754; PubMed Central PMCID: PMCPMC8011122.

13.   Valdivieso-Garcia A, Imgrund R, Deckert A, Varughese BM, Harris K, Bunimov N, et al.

Cost analysis and antimicrobial susceptibility testing comparing the E test and the agar dilution

method in Campylobacter jejuni and Campylobacter coli. Diagn Microbiol Infect Dis.

2009;65(2):168-74. doi: 10.1016/j.diagmicrobio.2009.07.008. PubMed PMID: 19748428.

14.   Desjardins M, Lefebvre B, Lavallee C, Labbe AC, Mauffrey F, Martin I, et al. Gradient

diffusion susceptibility testing for Neisseria gonorrhoeae: an accurate alternative to agar dilution

in high-MIC strains? Access Microbiol. 2020;2(5):acmi000116. Epub 20200325. doi:

10.1099/acmi.0.000116. PubMed PMID: 32974579; PubMed Central PMCID:

PMCPMC7494190.

15.   Yasin RM, Suan KA, Meng CY. Comparison of E-test with agar dilution methods in

testing susceptibility of N. gonorrhoeae to azithromycin. Sex Transm Dis. 1997;24(5):257-60.

doi: 10.1097/00007435-199705000-00004. PubMed PMID: 9153733.

16.   Liu H, Taylor TH, Jr., Pettus K, Trees D. Assessment of Etest as an alternative to agar

dilution for antimicrobial susceptibility testing of Neisseria gonorrhoeae. J Clin Microbiol.

2014;52(5):1435-40. Epub 20140219. doi: 10.1128/JCM.02131-13. PubMed PMID: 24554750;

PubMed Central PMCID: PMCPMC3993651.

17.   McAuliffe GN, Smith M, Cooper G, Forster RF, Roberts SA. Variability in Azithromycin

Susceptibility Results for Neisseria gonorrhoeae Obtained Using Gradient MIC Strip and Agar

Dilution Techniques. J Clin Microbiol. 2019;57(12). Epub 20191122. doi: 10.1128/JCM.01353-

19. PubMed PMID: 31578264; PubMed Central PMCID: PMCPMC6879296.

18.   Papp JR, Rowlinson MC, O'Connor NP, Wholehan J, Razeq JH, Glennen A, et al.

Accuracy and reproducibility of the Etest to detect drug-resistant Neisseria gonorrhoeae to

contemporary treatment. J Med Microbiol. 2018;67(1):68-73. Epub 20171208. doi:

10.1099/jmm.0.000651. PubMed PMID: 29219803; PubMed Central PMCID:

PMCPMC6739835.

19.   Clinical and Laboratory Standards Institute (CLSI) Verification of commercial microbial

identification and antimicrobial Susceptibility Testing Systems. 1st ed. CLSI Guideline M52.

CLSI, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.

20.   St Cyr S, Barbee L, Workowski KA, Bachmann LH, Pham C, Schlanger K, Torrone E,

Weinstock H, Kersh EN, Thorpe P. Update to CDC's Treatment Guidelines for Gonococcal

Infection, 2020. MMWR Morb Mortal Wkly Rep. 2020 Dec 18;69(50):1911-1916. doi:

10.15585/mmwr.mm6950a6. PMID: 33332296; PubMed Central PMCID: PMC7745960.

https://www.cdc.gov/std/statistics/2022/default.htm

21.   Kuo CF, Lio CF, Chen HT, Wang YT, Ma KS, Chou YT, et al. Discordance of

vancomycin minimum inhibitory concentration for methicillin-resistant Staphylococcus aureus at

2 mug/mL between Vitek II, E-test, and Broth Microdilution. PeerJ. 2020;8:e8963. Epub

20200511. doi: 10.7717/peerj.8963. PubMed PMID: 32435531; PubMed Central PMCID:

PMCPMC7224226.

22.   Berghaus LJ, Giguere S, Guldbech K, Warner E, Ugorji U, Berghaus RD. Comparison of

Etest, disk diffusion, and broth macrodilution for in vitro susceptibility testing of Rhodococcus

equi. J Clin Microbiol. 2015;53(1):314-8. Epub 20141105. doi: 10.1128/JCM.02673-14. PubMed

PMID: 25378571; PubMed Central PMCID: PMCPMC4290945.

23.   Jousset AB, Bernabeu S, Emeraud C, Bonnin RA, Lomont A, Zahar JR, et al. Evaluation

of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales. J

Glob Antimicrob Resist. 2023;32:78-84. Epub 20230126. doi: 10.1016/j.jgar.2023.01.003.

PubMed PMID: 36708769.

24.   Varela NP, Friendship R, Dewey C, Valdivieso A. Comparison of agar dilution and E-

test for antimicrobial susceptibility testing of Campylobacter coil isolates recovered from 80

Ontario swine farms. Can J Vet Res. 2008;72(2):168-74. PubMed PMID: 18505206; PubMed

Central PMCID: PMCPMC2276902.

25.   Baverud V, Gunnarsson A, Karlsson M, Franklin A. Antimicrobial susceptibility of

equine and environmental isolates of Clostridium difficile. Microb Drug Resist. 2004;10(1):57-

63. doi: 10.1089/107662904323047817. PubMed PMID: 15140395.

26.   Tabrizi SN, Unemo M, Limnios AE, Hogan TR, Hjelmevoll SO, Garland SM, Tapsall J.

Evaluation of six commercial nucleic acid amplification tests for detection of Neisseria

gonorrhoeae and other Neisseria species. J Clin Microbiol. 2011;49(10):3610-5. Epub 20110803.

doi: 10.1128/JCM.01217-11. PubMed PMID: 21813721; PubMed Central PMCID:

PMCPMC3187337.

27.   Andersson DI, Nicoloff H, Hjort K. Mechanisms and clinical relevance of bacterial

heteroresistance. Nat Rev Microbiol. 2019;17(8):479-96. Epub 20190624. doi: 10.1038/s41579-

019-0218-1. PubMed PMID: 31235888.

28.   Pham CD, Nash E, Liu H, Schmerer MW, Sharpe S, Woods G, et al. Atypical Mutation

in Neisseria gonorrhoeae 23S rRNA Associated with High-Level Azithromycin Resistance.

Antimicrob Agents Chemother. 2021;65(2). Epub 20210120. doi: 10.1128/AAC.00885-20.

PubMed PMID: 33139288; PubMed Central PMCID: PMCPMC7848993.

29.   Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial

Susceptibility Tests for Bacteria That Grow Aerobically. 11th ed. CLSI Guideline M07. CLSI,

950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2018.

30.   Culyba MJ, Van Tyne D. Bacterial evolution during human infection: Adapt and live or

adapt and die. PLoS Pathog. 2021;17(9):e1009872. Epub 20210909. doi:

10.1371/journal.ppat.1009872. PubMed PMID: 34499699; PubMed Central PMCID:

PMCPMC8428787.

398
399 **Figure 1.** Yearly MIC pair equivalency (left) and concordance (right) rates from SURRG and

400 ARLN lab results for azithromycin, cefixime, and ceftriaxone from 2018 to 2024.

402 **Table 1.** Sample sizes and Spearman's rank correlation for agar dilution and Etest pairs

Antibiotic	*n* pairs	Spearman's ρ	p-value
Azithromycin	1,893	0.767	<0.001
Cefixime	1,901	0.522	<0.001
Ceftriaxone	1,892	0.781	<0.001

404 **Table 2.** MIC equivalency and essential agreement of azithromycin, cefixime and ceftriaxone

Antibiotic	N Pairs	Dilution Difference					Essential Agreement
		≤ -2	-1	0	1	≥ 2	
Azithromycin	1,893	69 (3.6%)	434 (23%)	1054 (56%)	312 (16%)	24 (1.3%)	1,800 (95%)
Cefixime	1,901	20 (1.1%)	313 (16%)	1482 (78%)	80 (4.2%)	6 (0.3%)	1,875 (98%)
Ceftriaxone	1,892	78 (4.1%)	504 (27%)	1141 (60%)	150 (8.0%)	19 (1.0%)	1,795 (95%)

406 **Table 3.** MIC equivalency and essential agreement of azithromycin, 2018-2023

Azithromycin	N Pairs	Dilution Difference					Essential Agreement
		≤ -2	-1	0	1	≥ 2	
Year, n (%)							
2018	192	2 (1.0%)	29 (15%)	133 (69%)	26 (14%)	2 (1.0%)	188 (98%)
2019	385	7 (1.8%)	59 (15%)	230 (60%)	81 (21%)	8 (2.1%)	370 (96%)
2020	419	15 (3.6%)	86 (21%)	218 (52%)	92 (22%)	8 (1.9%)	396 (95%)
2021	212	20 (9.4%)	85 (40%)	94 (44%)	13 (6.1%)	0 (0%)	192 (91%)
2022	286	16 (5.6%)	83 (29%)	149 (52%)	34 (12%)	4 (1.4%)	266 (93%)
2023	257	5 (1.9%)	64 (25%)	139 (54%)	47 (18%)	2 (0.8%)	250 (97%)
2024	142	4 (2.8%)	28 (20%)	91 (64%)	19 (13%)	0 (0%)	138 (97%)

409 **Table 4.** MIC equivalency and essential agreement of cefixime, 2018-2023

Cefixime		Dilution Difference					
	N Pairs	≤ -2	-1	0	1	≥ 2	Essential Agreement
Year, n (%)							
2018	191	0 (0%)	12 (6.3%)	165 (86%)	13 (6.8%)	1 (0.5%)	190 (99%)
2019	385	0 (0%)	50 (13%)	316 (82%)	18 (4.7%)	1 (0.3%)	384 (100%)
2020	419	4 (1.0%)	90 (21%)	317 (76%)	8 (1.9%)	0 (0%)	415 (99%)
2021	213	2 (0.9%)	24 (11%)	174 (82%)	11 (5.2%)	2 (0.9%)	209 (98%)
2022	274	2 (0.7%)	45 (16%)	207 (76%)	19 (6.9%)	1 (0.4%)	271 (99%)
2023	255	9 (3.5%)	71 (28%)	173 (68%)	2 (0.8%)	0 (0%)	246 (96%)
2024	164	3 (1.8%)	21 (13%)	130 (79%)	9 (5.5%)	1 (0.6%)	160 (98%)

Table 5. MIC equivalency and essential agreement of ceftriaxone, 2018-2023

Ceftriaxone		Dilution Difference					
	N Pairs	≤ -2	-1	0	1	≥ 2	Essential Agreement
Year, n (%)							
2018	192	1 (0.5%)	6 (3.1%)	184 (96%)	1 (0.5%)	0 (0%)	191 (99%)
2019	385	4 (1.0%)	29 (7.5%)	342 (89%)	8 (2.1%)	2 (0.5%)	379 (98%)
2020	419	9 (2.1%)	117 (28%)	254 (61%)	36 (8.6%)	3 (0.7%)	407 (97%)
2021	213	5 (2.3%)	57 (27%)	116 (54%)	30 (14%)	5 (2.3%)	203 (95%)
2022	267	17 (6.4%)	102 (38%)	116 (43%)	31 (12%)	1 (0.4%)	249 (93%)
2023	249	21 (8.4%)	133 (53%)	77 (31%)	12 (4.8%)	6 (2.4%)	222 (89%)
2024	167	21 (13%)	60 (36%)	52 (31%)	32 (19%)	2 (1.2%)	144 (86%)

Table 6. Total and Percentage of Underestimates and Overestimates Made by the Etest

Antibiotic	N Pairs	Underestimate (≤ -2)	Overestimate (≥ 2)	p-value
Azithromycin	93	69 (77%)	24 (23%)	$< .001$
Cefixime	26	20 (74%)	6 (26%)	$< .001$
Ceftriaxone	97	78 (80%)	19 (20%)	$< .001$

Table 7. MIC equivalency and essential agreement of azithromycin by anatomical site

Azithromycin		Dilution Difference					
	N Pairs	≤ -2	-1	0	1	≥ 2	Essential Agreement
Specimen Source, n (%)							
Blood	1	0 (0%)	0 (0%)	0 (0%)	1	0 (0%)	1 (100%)

						(100%)	
Endocervical	171	7 (4.1%)	39 (23%)	85 (50%)	39 (23%)	1 (0.6%)	163 (95%)
Pharyngeal	314	11 (3.5%)	76 (24%)	173 (55%)	50 (16%)	4 (1.3%)	299 (95%)
Rectal	137	3 (2.2%)	31 (23%)	74 (54%)	29 (21%)	0 (0%)	134 (98%)
Urethral	1,123	44 (3.9%)	257 (23%)	644 (57%)	162 (14%)	16 (1.4%)	1,063 (95%)
Vaginal	147	4 (2.7%)	31 (21%)	78 (53%)	31 (21%)	3 (2.0%)	140 (95%)

419 **Table 8.** MIC equivalency and essential agreement of cefixime by anatomical site

Cefixime		**Dilution Difference**					
	N Pairs	**≤ -2**	**-1**	**0**	**1**	**≥ 2**	**Essential Agreement**
Specimen Source, n (%)							
Blood	1	0 (0%)	1 (100%)	0 (0%)	0 (0%)	0 (0%)	1 (100%)
Endocervical	169	1 (0.6%)	25 (15%)	130 (77%)	11 (6.5%)	2 (1.2%)	166 (98%)
Pharyngeal	319	4 (1.3%)	63 (20%)	234 (73%)	17 (5.3%)	1 (0.3%)	314 (98%)
Rectal	133	3 (2.3%)	27 (20%)	100 (75%)	3 (2.3%)	0 (0%)	130 (98%)
Urethral	1,133	11 (1.0%)	180 (16%)	902 (80%)	37 (3.3%)	3 (0.3%)	1,119 (99%)
Vaginal	146	1 (0.7%)	17 (12%)	116 (79%)	12 (8.2%)	0 (0%)	145 (99%)

421 **Table 9.** MIC equivalency and essential agreement of ceftriaxone by anatomical site

Ceftriaxone		Dilution Difference					
	N Pairs	≤ -2	-1	0	1	≥ 2	Essential Agreement
Specimen Source, n (%)							
Blood	1	0 (0%)	0 (0%)	0 (0%)	1 (100%)	0 (0%)	1 (100%)
Endocervical	170	7 (4.1%)	36 (21%)	111 (65%)	16 (9.4%)	0 (0%)	163 (96%)
Pharyngeal	316	15 (4.7%)	84 (27%)	192 (61%)	23 (7.3%)	2 (0.6%)	299 (95%)
Rectal	131	7 (5.3%)	46 (35%)	66 (50%)	10 (7.6%)	2 (1.5%)	122 (93%)
Urethral	1,127	45 (4.0%)	308 (27%)	674 (60%)	88 (7.8%)	12 (1.1%)	1,070 (95%)
Vaginal	147	4 (2.7%)	30 (20%)	98 (67%)	12 (8.2%)	3 (2.0%)	140 (95%)

423 **Table 10.** Number of major disagreements in alerts between the Etest and Agar Dilution

Antibiotic	Major Disagreements
Azithromycin	49
Cefixime	4
Ceftriaxone	1

Acknowledgements

We gratefully acknowledge the support and collaboration of the Centers for Disease Control and

Prevention (CDC) Antimicrobial Resistance Laboratory Network (ARLN) and the North

Carolina Strengthening the US Response to Resistant Gonorrhea (NC SURRG) network

including our partners at the Centers for Disease Control and Prevention, the Guilford County

Department of Public Health, the North Carolina Department of Health and Human Services, and

Wake Forest University School of Medicine.

Contributions

JM, JW, MD, BB data analysis, data interpretation, manuscript preparation and review. CJM,

EP, and CT data interpretation, manuscript preparation and review. MD, JM, JW, BB and CJM

had direct access to and verified the underlying data reported in the manuscript.

Supplemental Digital Content

Supplemental Digital Content 1.docx